<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0">
  <channel>
    <title><![CDATA[Seizures]]></title>
    <link>https://www.leadingmarketresearch.com/pharmaceuticals-biotechnology/pharmaceuticals/therapeutic-areas/seizures</link>
    <description><![CDATA[Seizures]]></description>
    <pubDate>Sat, 13 Jun 2026 23:29:14 +0000</pubDate>
    <generator>Zend_Feed</generator>
    <docs>http://blogs.law.harvard.edu/tech/rss</docs>
    <item>
      <title><![CDATA[Seizures - Pipeline Review, H2 2016]]></title>
      <link>https://www.leadingmarketresearch.com/seizures-pipeline-review-h2-2016</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct’s, ‘Seizures - Pipeline Review, H2 2016’, provides an overview of the Seizures pipeline landscape. <br><br>The report provides comprehensive information on the therapeutics under development for Seizures, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Seizures and features dormant and discontinued projects. <br><br>Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured pres...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-184611"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Thu, 15 Sep 2016 21:22:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Seizures - Pipeline Review, H1 2016]]></title>
      <link>https://www.leadingmarketresearch.com/seizures-pipeline-review-h1-2016</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Global Markets Direct’s, ‘Seizures - Pipeline Review, H1 2016’, provides an overview of the Seizures pipeline landscape. <br><br>The report provides comprehensive information on the therapeutics under development for Seizures, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Seizures and features dormant and discontinued projects. <br><br>Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured pres...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-173906"><span class="price">$2,000.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Sat, 28 May 2016 19:12:44 +0000</pubDate>
    </item>
  </channel>
</rss>
